South Africa Drops J&J Bedaquiline Scrutiny After Generic Market Opens Up
J&J Agrees To Withdraw 2027 Secondary Patent; 40% Price Cut Agreed With Buyer
Johnson & Johnson’s actions to promote generic competition and lower the price for its crucial tuberculosis treatment, Sirturo (bedaquiline), have satisfied an investigation launched by South Africa’s Competition Commission.
